Literature DB >> 12555997

Prognostic factors in anal carcinoma.

Claus Fenger1.   

Abstract

The pathologist's role in the evaluation of patients with anal squamous carcinoma is now largely restricted to establishing the diagnosis on small biopsies. Staging is performed by imaging techniques and grading is uncertain as the biopsy may not be representative of the whole tumour. Histological subtyping is unreliable and has not been proven to be of prognostic significance. A considerable effort resulting in nearly 50 reports on cytogenetic, flow cytometric, immunohistochemical and other investigations has given new insight into pathogenesis but little guidance with regard to the individual prognosis or choice of treatment. It is concluded that future research should concentrate on larger, probably multicentre series using standardised methods and criteria for evaluation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12555997     DOI: 10.1080/0031302021000035956

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  4 in total

Review 1.  Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy.

Authors:  Guillaume Klausner; Eivind Blais; Raphaël Jumeau; Julian Biau; Mailys de Meric de Bellefon; Mahmut Ozsahin; Thomas Zilli; Raymond Miralbell; Juliette Thariat; Idriss Troussier
Journal:  Med Oncol       Date:  2018-08-20       Impact factor: 3.064

2.  Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus.

Authors:  Abdelkarim S Allal; Marie-Anne Bründler; Pascal Gervaz
Journal:  Int J Colorectal Dis       Date:  2004-10-02       Impact factor: 2.571

3.  Prognostic factors for squamous cell cancer of the anal canal.

Authors:  Prajnan Das; Christopher H Crane; Cathy Eng; Jaffer A Ajani
Journal:  Gastrointest Cancer Res       Date:  2008-01

4.  Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients.

Authors:  M P Myklebust; Ø Fluge; H Immervoll; A Skarstein; L Balteskard; O Bruland; O Dahl
Journal:  Br J Cancer       Date:  2012-02-14       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.